Skip to main content
SpringerLink
Log in

The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Objectives

Hyperthermic intraperitoneal chemotherapy (HIPEC) is an intriguing method of delivery wherein the cytotoxic agent is continuously heated and circulated throughout the peritoneum in an attempt to bolster drug efficacy. Despite HIPEC’s potential, ascertaining the optimal dose without compromising patient tolerability remains indeterminate.

Methods

We retrospectively evaluated 52 advanced stage ovarian cancer patients who were treated with consolidation HIPEC with carboplatin at varying doses (e.g., AUC 6, 8 or 10) subsequent to optimal debulking surgery and the attainment of a clinical complete response to their primary chemotherapy regimen. The following patient and operative characteristics were abstracted: demographics, surgery and pathology data, chemotherapy regimen, intraoperative results, toxicity, postoperative complications, length of hospital stay and survival data.

Results

Twelve patients received HIPEC carboplatin at an AUC 6, 15 subjects were treated with carboplatin at an AUC 8 and 25 underwent carboplatin at an AUC 10. There were no intraoperative complications during the administration of HIPEC; mean estimated blood loss was 50 mL and length of hospital stay was 1.65 days. In the overall study population, 5 patients developed grade 3/4 anemia and 33 subjects exhibited grade ≤2 thrombocytopenia and neutropenia. Thirteen patients also developed grade ≤2 nausea on postoperative day 1, which was successfully addressed with anti-emetic therapy; there were no hospital readmissions.

Conclusions

The results from the current evaluation suggest that consolidation hyperthermic intraperitoneal chemotherapy with carboplatin is both feasible and reasonably tolerated, even at an AUC of 10. However, additional, randomized study of this procedure incorporating chemotherapy dose escalation with a more extensive patient population is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mulier S, Claes JP, Dierieck V et al (2012) Survival benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des 18:3793–3803

    Article  CAS  PubMed  Google Scholar 

  2. Cotte E, Passot G, Gilly FN et al (2010) Selection of patients and staging of peritoneal surface malignancies. World J Gastrointest Oncol 2:31–35

    Article  PubMed Central  PubMed  Google Scholar 

  3. Argenta PA, Sueblinvong T, Geller MA et al (2013) Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study. Gynecol Oncol 129:81–85

    Article  CAS  PubMed  Google Scholar 

  4. Zhou M, Yu P, Qu X et al (2013) Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis. PLoS One 8:e81858

    Article  PubMed Central  PubMed  Google Scholar 

  5. Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483

    Article  CAS  PubMed  Google Scholar 

  6. Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496

    Article  CAS  PubMed  Google Scholar 

  7. Markman M, Liu PY, Wilczynski S et al (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460–2465

    Article  CAS  PubMed  Google Scholar 

  8. Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43

    Article  CAS  PubMed  Google Scholar 

  9. van der Vange N, van Goethem AR, Zoetmulder FA (2000) Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 26:663–668

    Article  PubMed  Google Scholar 

  10. Yoshida Y, Sasaki H, Kurokawa T et al (2005) Efficacy of intraperitoneal continuous hyperthermic chemotherapy as consolidation therapy in patients with advanced epithelial ovarian cancer: a long-term follow-up. Oncol Rep 13:121–125

    CAS  PubMed  Google Scholar 

  11. Salle B, Gilly FN, Carry PY et al (1993) Intraperitoneal chemo-hyperthermia in the treatment of peritoneal carcinomatosis of ovarian origin. Initial cases, physiopathologic data. J Gynecol Obstet Biol Reprod 22:369–371

    CAS  Google Scholar 

  12. Francescutti V, Rivera L, Seshadri M et al (2013) The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis. Oncol Rep 30:35–42

    PubMed Central  CAS  PubMed  Google Scholar 

  13. Arjona-Sanchez A, Muñoz-Casares C, Ortega-Salas R et al (2014) Long-term survival with peritoneal mucinous carcinomatosis from intraductal mucinous papillary pancreatic carcinoma treated with complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia 30:408–411

    Article  CAS  PubMed  Google Scholar 

  14. Tabrizian P, Shrager B, Jibara G et al (2014) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. J Gastrointest Surg 18:1024–1031

    Article  PubMed  Google Scholar 

  15. Ansaloni L, Agnoletti V, Amadori A et al (2012) Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 22:778–785

    Article  PubMed  Google Scholar 

  16. Gori J, Castaño R, Toziano M et al (2005) Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 15:233–239

    Article  CAS  PubMed  Google Scholar 

  17. Lim MC, Kang S, Choi J et al (2009) Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study. Ann Surg Oncol 16:993–1000

    Article  PubMed  Google Scholar 

  18. Lim SJ, Cormier JN, Feig BW et al (2007) Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann Surg Oncol 14:2309–2318

    Article  PubMed  Google Scholar 

  19. López-Basave HN, Morales-Vasquez F, Mendez-Herrera C et al (2014) Intensive care unit admission after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Is it necessary? J Oncol 2014:307317

    Article  PubMed Central  PubMed  Google Scholar 

  20. Lentz SS, Miller BE, Kucera GL et al (2007) Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma. Gynecol Oncol 106:207–210

    Article  CAS  PubMed  Google Scholar 

  21. Ryu KS, Kim JH, Ko HS et al (2004) Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 94:325–332

    Article  CAS  PubMed  Google Scholar 

  22. Elias D, Gilly F, Boutitie F et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 28:63–68

    Article  PubMed  Google Scholar 

  23. Bristow RE, Montz FJ, Lagasse LD et al (1999) Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72:278–287

    Article  CAS  PubMed  Google Scholar 

  24. Therasse P, Arbuck SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  25. Rustin GJ, Marples M, Nelstrop AE (2001) Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19:4054–4057

    CAS  PubMed  Google Scholar 

  26. NIH (2010) Common terminology criteria for adverse events (version 4.03). National Institute of Health, Washington

    Google Scholar 

  27. Rettenmaier MA, Abaid LN, Erwin MR et al (2009) A retrospective review of the GelPort system in single-port access pelvic surgery. J Minim Invasive Gynecol 16:743–747

    Article  PubMed  Google Scholar 

  28. Calvert AH, Newell DR, Gunbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756

    CAS  PubMed  Google Scholar 

  29. Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194–3200

    Article  CAS  PubMed  Google Scholar 

  30. McGuire WP, Hoskin WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV EOC. N Engl J Med 334:1–6

    Article  CAS  PubMed  Google Scholar 

  31. Los G, van Vugt MJ, Pinedo HM (1994) Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 69:235–241

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Brown JV 3rd, Micha JP, Rettenmaier MA et al (2010) A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma. Int J Gynecol Cancer 20:1132–1136

    Article  PubMed  Google Scholar 

  33. Miyagi Y, Fujiwara K, Kigawa J et al (2005) Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin—a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol 99:591–596

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant from the Nancy Yeary Women’s Cancer Research Foundation.

Conflict of interest

The authors deny any conflicts of interest associated with this manuscript.

Author information

Authors and Affiliations

  1. Gynecologic Oncology Associates, 351 Hospital Road, Suite 507, Newport Beach, CA, 92663, USA

    Mark A. Rettenmaier, Alberto A. Mendivil, Lisa N. Abaid, John V. Brown III, John P. Micha, Amber M. Wilcox & Bram H. Goldstein

Authors
  1. Mark A. Rettenmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto A. Mendivil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lisa N. Abaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John V. Brown III
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John P. Micha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amber M. Wilcox
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bram H. Goldstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bram H. Goldstein.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rettenmaier, M.A., Mendivil, A.A., Abaid, L.N. et al. The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma. Arch Gynecol Obstet 291, 1381–1386 (2015). https://doi.org/10.1007/s00404-014-3590-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-014-3590-0

Keywords

Search

Navigation